Virtual Poster Session in NETs From Barcelona and Boston - priME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in NETs From Barcelona and Boston

Practical Application of Key Data Presented During the 2019 Annual Conferences in Barcelona and Boston

View Activities

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

View poster presentations and downloadable slides covering the most up-to-date clinical trial data on neuroendocrine tumors (NETs) presented at the 2019 Annual Oncology Meeting in Barcelona and the NANETS 11th Annual Multidisciplinary NET Disease Symposium in Boston.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Oct 31, 2019

Expiration Date

Oct 31, 2020

Abstracts Presented in Barcelona

Jianmin Xu, MD, PhD

Abstract #LBA76: Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)

Featured Expert: Jianmin Xu, MD, PhD

Philippe Ruszniewski, MD

Abstract #1388P: Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120 mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen

Featured Expert: Philippe Ruszniewski, MD

Abstracts Presented in Boston

Lowell Anthony, MD

Abstract #C1: The TELEPATH phase 3 study: An analysis of long-term treatment with telotristat ethyl in patients with carcinoid syndrome symptoms

Featured Expert: Lowell Anthony, MD

Jonathan Strosberg, MD

Abstract #C6: Randomized phase II trial of pazopanib versus placebo in patients (Pts) with progressive carcinoid tumors (CARC) (Alliance A021202)

Featured Expert: Jonathan Strosberg, MD

Raj Srirajaskanthan, MD, MRCP

Abstract #C13: Tumor growth rate (TGR) to monitor growth/predict response to lanreotide autogel use before, during and after PRRT in advanced GEP-NETS: Data from the PRELUDE study

Featured Expert: Raj Srirajaskanthan, MD, MRCP

Daphne Adelman, BSN, MBA

Abstract #C17: Enhancing patient care via co-creation and validation of a new and improved delivery system for lanreotide autogel/depot: Focus on its evaluation by US healthcare professionals

Featured Expert: Daphne Adelman, BSN, MBA

Jordan Cloyd, MD

Abstract #C50: Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors

Featured Expert: Jordan Cloyd, MD

Winson Cheung, MD, MPH, FRCPC

Abstract #P12: Real-world comparative analysis of lanreotide and octreotide long-acting release (Lar) use for neuroendocrine tumors (NETs) in Canada

Featured Expert: Winson Cheung, MD, MPH, FRCPC

Jonathan Strosberg, MD

Abstract #T2: Analyses of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE vs. high dose OCTREOTIDE in progressive midgut neuroendocrine tumors

Featured Expert: Jonathan Strosberg, MD

  • Daphne Adelman, BSN, MBAFeinberg School of Medicine
    Northwestern University
    Chicago, Illinois, United States
  • Lowell Anthony, MDMarkey Cancer Center
    University of Kentucky
    Lexington, Kentucky, United States
  • Winson Cheung, MD, MPH, FRCPCCumming School of Medicine
    University of Calgary
    Alberta, Canada
  • Jordan Cloyd, MDThe Ohio State University Wexner Medical Center
    Columbus, Ohio, United States
  • Philippe Ruszniewski, MDUniversity of Paris VII
    Beaujon Hospital
    Paris, France
  • Raj Srirajaskanthan, MD, MRCPKing's College Hospital
    London, United Kingdom
  • Jonathan Strosberg, MDMoffitt Cancer Center
    Tampa, Florida, United States
  • Jianmin Xu, MD, PhDZhongshan Hospital
    Fudan University
    Shanghai, China

This activity is intended for medical oncologists, endocrinologists, gastroenterologists, and other healthcare providers based outside of the United States who are involved in the management of patients with neuroendocrine tumors.

Upon completion of this activity, participants will:

Have increased knowledge regarding the

  • Key data on NETs presented at the conferences

Have greater competence related to

  • Applying key data on NETs from the conferences to clinical practice

This educational activity is supported by a grant from Ipsen.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Daphne Adelman, BSN, MBA, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Crinetics; Novo Nordisk; Ipsen
  • Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Novo Nordisk

Winson Cheung, MD, MPH, FRCPC, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation
  • Received grants for clinical research from: Ipsen

Jordan Cloyd, MD, has disclosed no relevant financial relationships.

Lowell Anthony, MD, FACEP, has disclosed no relevant financial relationships.

Philippe Ruszniewski, MD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: AAA Pharmaceutical; Ipsen; ITH Pharma; Novartis Pharmaceuticals Corporation
  • Received grants for clinical research from: AAA Pharmaceutical; Ipsen; ITH Pharma

Raj Srirajaskanthan, MB, BS, FRCP, MD (Res), BSc(Hons), has disclosed no relevant financial relationships.

Jonathan Strosberg, MD, has disclosed the following relevant financial relationships:

  • Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation
  • Served as a speaker or a member of a speakers bureau for: Ipsen; Lexicon Pharmaceuticals, Inc.
  • Received grants for clinical research from: Novartis Pharmaceuticals Corporation

Jianming Xu, MD, PhD, has disclosed no relevant financial relationships.

The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.

Content Reviewers

Amy Bernard, MS, BSN, RN-BC, CHCP
Director, Accreditation and Compliance
Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE
Associate Director, Accreditation and Compliance Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Esther Nyarko, PharmD
Associate Director, Accreditation and Compliance
Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Cindy Tryniszewski, MSN, RN, FAEN
Senior Director, Content Development
Cindy Tryniszewski, MSN, RN, FAEN has disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.